Retatrutides dosing in trials also follows a multi-step escalation, but the exact regimen that would reach the market if it is approved is not yet finalized, and any figures circulating for retatrutide reflect trial protocols rather than an approved label
Randomized Trial of Two Over-the-Counter Laxatives to Treat GLP-1 Constipation
Section 503A pharmacies make prescription-specific compounds based on an individual prescription from a licensed clinician
Liu J, Liu H, Liu H, Teng Y, Qin N, Ren X, Xia X (2023) Live and pasteurized Akkermansia muciniphila decrease susceptibility to Salmonella Typhimurium infection in mice
Try the BMI Calculator Table of contents The 30-second answer The full SURMOUNT-1 dose-response data Why "highest dose = best" isn't always true The standard dose escalation schedule When to stop escalating: signs your current dose is working The 5 percent rule at month 3 and month 6 Why some patients don't need to reach 15 mg Side effects across the dose ladder Maintenance vs continued escalation FAQ The full SURMOUNT-1 dose-response data SURMOUNT-1 (Jastreboff et al., NEJM 2022) is the phase 3 registration trial that earned Zepbound its FDA approval for weight management
Liraglutide received NICE approval (TA664) in 2020 for use through specialist weight management services, but the criteria are narrow, and availability has been limited in practice